Close

Anti-MAGEA3 (EVDPIGHLY) TCR, pMSGV1 (TCR-L062)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-MAGEA3 T cell receptor (TCR) is constructed for the engineering of T cell to target Human MAGEA3. The T cells are genetically modified through transduction with a retroviral vector expressing MAGEA3-specific T cell receptor. And the vector product was designed for the treatment of Melanoma.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • MAGE-A3
  • Target Species
  • Human
  • Epitope
  • EVDPIGHLY
  • Format
  • Non-modified TCR
  • Allele
  • HLA-A1
  • Targeting Diseases
  • Melanoma
  • Vector Name
  • pMSGV1
  • Vector Length
  • 6700-8070bp
  • Vector Type
  • retroviral vector
  • Host Species
  • Human

Target

  • Official Symbol
  • MAGEA3
  • Introduction
  • This gene is a member of the MAGEA gene family. The members of this family encode proteins with
    50 to 80% sequence identity to each other. The promoters and first exons of the MAGEA genes show
    considerable variability, suggesting that the existence of this gene family enables the same function
    to be expressed under different transcriptional controls. The MAGEA genes are clustered at
    chromosomal location Xq28. They have been implicated in some hereditary disorders, such as
    dyskeratosis congenita.
    Alternative Names MAGEA3; Cancer/Testis

Customer Reviews and Q&As

There are currently no customer reviews or questions for Human anti-MAGEA3 (EVDPIGHLY) T Cell Receptor, pMSGV1 (TCR-L062). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.